Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220235
Title: A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis.
Author: Palomino Echeverria, Sara
Huergo, Estefania
Ortega Legarreta, Asier
Uson Raposo, Eva M.
Aguilar, Ferran
de la Peña-Ramírez, Carlos
López Vicario, Cristina
Alessandria, Carlo
Laleman, Wim
Queiroz Farias, Alberto
Moreau, Richard
Fernández, Javier
Arroyo, Vicente
Caraceni, Paolo
Lagani, Vincenzo
Sánchez Garrido, Cristina
Clària i Enrich, Joan
Tegnér, Jesper
Trebicka, Jonel
Kiani, Narsis A.
Planell Picola, Núria
Rautou, Pierre-Emmanuel
Gomez Cabrero, David
Keywords: Assaigs clínics
Cirrosi hepàtica
Clinical trials
Hepatic cirrhosis
Issue Date: 2024
Publisher: BioMed Central
Abstract: Background: Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predicting scores, potentially overlooking crucial elements contributing to heterogeneity without necessarily impacting prognosis. Methods: To address patient heterogeneity, we developed ClustALL, a computational pipeline that simultaneously faces diverse clinical data challenges like mixed types, missing values, and collinearity. ClustALL enables the unsupervised identification of patient stratifications while filtering for stratifications that are robust against minor variations in the population (population-based) and against limited adjustments in the algorithm's parameters (parameter-based). Results: Applied to a European cohort of patients with acutely decompensated cirrhosis (n = 766), ClustALL identified five robust stratifications, using only data at hospital admission. All stratifications included markers of impaired liver function and number of organ dysfunction or failure, and most included precipitating events. When focusing on one of these stratifications, patients were categorized into three clusters characterized by typical clinical features; notably, the 3-cluster stratification showed a prognostic value. Re-assessment of patient stratification during follow-up delineated patients' outcomes, with further improvement of the prognostic value of the stratification. We validated these findings in an independent prospective multicentre cohort of patients from Latin America (n = 580). Conclusions: By applying ClustALL to patients with acutely decompensated cirrhosis, we identified three patient clusters. Following these clusters over time offers insights that could guide future clinical trial design. ClustALL is a novel and robust stratification method capable of addressing the multiple challenges of patient stratification in most complex diseases.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s12967-024-05386-2
It is part of: Journal of Translational Medicine, 2024, vol. 22, num.1
URI: https://hdl.handle.net/2445/220235
Related resource: https://doi.org/10.1186/s12967-024-05386-2
ISSN: 1479-5876
Appears in Collections:Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
886965.pdf7.12 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons